v3.25.2
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
Jun. 30, 2025
Dec. 31, 2024
Assets    
Cash and cash equivalents $ 10,363,714 $ 13,476,331
Prepaid clinical trial costs 104,447 540,601
Prepaid expenses and other current assets 346,964 666,435
Total current assets 10,815,125 14,683,367
Non-current prepaid clinical trial costs 819,721 819,721
Total Assets 11,634,846 15,503,088
Liabilities    
Short-term debt 113,246 458,154
Accounts payable 4,968,688 6,283,430
Accrued clinical expenses 5,470,185 6,723,719
Accrued compensation 602,592 635,587
Other accrued liabilities 922,592 500,616
Total current liabilities 12,077,303 14,601,506
Warrant liabilities 16,690 89,010
Total Liabilities 12,093,993 14,690,516
Commitments and Contingencies  
Stockholders’ Equity    
Common stock, par value of $0.0001; 315,000,000 shares authorized; 68,003,613 and 46,579,199 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 6,800 4,658
Preferred Stock, par value of $0.0001; 10,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024 0 0
Additional paid-in capital 176,293,553 165,080,964
Accumulated deficit (176,759,500) (164,273,050)
Total stockholders' equity (deficit) (459,147) 812,572
Total Liabilities and Stockholders’ Equity (Deficit) $ 11,634,846 $ 15,503,088